endpts.com·May 13, 2026
Abeona Therapeutics has shifted its focus from eye gene therapies to developing solid tumor T cell therapies, while also providing updates on companies including Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech, and C4 Therapeutics.
Abeona's pivot from eye gene therapies to solid tumor T cell therapy highlights a strategic shift towards targeting solid tumors, which could signal new opportunities for innovation and partnerships in the oncology space, particularly for those interested in leveraging T cell therapies. This move underscores the importance of adaptability and responsiveness to market demands in biotech.